

**ASX Announcement | 25 September 2020
Visioneering Technologies (ASX:VTI)**

Notice of Option Exercise Period

Atlanta, Georgia, USA, 24 September 2020 (25 September 2020 Australia): US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses (NVMF) **Visioneering Technologies, Inc. (ASX: VTI)** ('Visioneering', 'VTI' or 'the Company') confirms that in accordance with the Notice of Annual General Meeting describing the Placement and the Security Purchase Plan (**SPP**), the Exercise Date for the unlisted options (**New Options**) issued under the Placement and the SPP is the last day of each month, with the next Exercise Date being 30 September 2020.

New Option holders who wish to exercise all or part of their New Options must give the Share Registry an Exercise of Options Notice form, together with payment of the exercise monies payable to the Company in connection with the Options being exercised (being \$0.028 (2.8 cents) per New Option) prior to 5.00pm (Sydney time) on Wednesday, 30 September 2020.

To assist New Option holders, an Exercise of Options Notice form is attached to this announcement. For your convenience, the Company also will post a copy of the form to the corporate governance section of VTI's website: <https://vtivisioninvestors.com/documents/>

The Company shall within five business days after the relevant New Option Exercise Date, subject to receipt of an Exercise of Options Notice form and cleared funds, issue CDIs in respect of the New Options exercised and dispatch a holding statement to the holder.

New Option holders are reminded that options are able to be exercised on the last day of the month up until (and including) 30 June 2022 (the date of their expiry).

Please refer to Annexure A to the Notice of Annual General Meeting (see ASX announcement on 13 May 2020) or to section 9.7 of the Prospectus for the SPP (see ASX announcement on 1 June 2020) for the full details on the terms and conditions of the New Options.

Ends

This release was authorized by the CEO, Stephen Snowdy, PhD.

For more information, please contact:

Visioneering Technologies

Stephen Snowdy
CEO & Executive Director

Investor & Media Relations

Julia Maguire
The Capital Network

E: ssnowdy@vtivision.com

M: +61 02 8999 3699

E: julia@thecapitalnetwork.com.au

NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lens Indication for Use Outside the United States: NaturalVue (etafilcon A) Multifocal Daily Disposable Soft (Hydrophilic) Contact Lenses are indicated for daily wear for the correction of refractive ametropia (myopia and hyperopia) and/or presbyopia, and myopia progression control in aphakic and/or non-aphakic persons with non-diseased eyes in powers from -20.00 to +20.00 dioptres and with non-diseased eyes who may require a reading addition of up to +3.00D. The lenses may be worn by persons who exhibit astigmatism of 2.00 dioptres or less that does not interfere with visual acuity.

About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism.

Headquartered in the US, Visioneering designs, manufactures, sells and distributes contact lenses. Its flagship product is the NaturalVue® Multifocal contact lens, and VTI has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across the United States, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

Foreign Ownership Restrictions

VTI's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product as well as our expectations with respect to our ability to develop and commercialize new products.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

ASX-VTI-IR37

How to complete this form

Exercise your Options in full or part

Registration Name(s)

The CHESS Despositary Interest(s) will be registered in the name(s) printed on the form.

A Options Exercised

Enter the number of Options you wish to exercise.

B Exercise Moneys

Enter the amount of exercise moneys. To calculate the amount payable, multiply the number of Options exercised by the exercise price.

C Payment

Make your cheque or bank draft payable to Visioneering Technologies, Inc. in Australian currency and cross it Not Negotiable. Your cheque or bank draft must be drawn on an Australian Bank.

Complete the cheque details in the boxes provided. The total amount must agree with the amount shown in box B.

Sufficient cleared funds must be held in your account as cheques returned unpaid may not be re-presented and may result in your Exercise of Options Notice being rejected. Pin (do not staple) your cheque(s) to the Exercise of Options Notice. Cash will not be accepted. Receipt for payment will not be forwarded.

D Signature(s)

You must sign the form as follows in the space provided:

Individual: where the holding is in one name, the Optionholder must sign.

Joint holding: the holding is in more than one name all of the Optionholders must sign.

Power of Attorney: to sign under Power of Attorney, you must have already lodged this document with the registry. Alternatively, attach an originally certified copy of the Power of Attorney to this form when you return it.

Companies: this form must be signed by either 2 Directors or a Director and a Company Secretary. Alternatively, where the company has a Sole Director and, pursuant to the Corporations Act, there is no Company Secretary, or where the Sole Director is also the Sole Company Secretary, that Director may sign alone. Delete titles as applicable.

Deceased Estate: all executors must sign and, if not already noted by the registry, a certified copy of Probate or Letters of Administration must accompany this form.

If you are in any doubt as to how to deal with this document, please consult your Financial or other Personal Advisor.

If you have any enquiries concerning your Optionholding, please contact Computershare Investor Services Pty Limited on 1300 850 505 or +61 3 9415 4000.

Lodgement of Notice

The Exercise of Options Notice must be received at the address below by no later than 5:00pm (AEST) on 30 June 2022.

Return the Exercise of Options Notice with cheque(s) attached to:

Visioneering Technologies, Inc.

C/- Computershare Investor Services Pty Limited

GPO BOX 2975 Melbourne Victoria 3001 Australia

Neither Computershare Investor Services Pty Limited nor Visioneering Technologies, Inc. accepts any responsibility if this Options Notice is lodge at any other address or by any other means.